Gujarat Terce Laboratories Ltd (GUJTERC) — shareholding pattern, promoter holding, financials and share price
About Gujarat Terce Laboratories Ltd (GUJTERC)
Gujarat Terce Laboratories Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as GUJTERC and on the BSE under scrip code 524314. Its ISIN is INE499G01013.
Incorporated in 1985. Gujarat Terce Laboratories Ltd is engaged in development, manufacturing, marketing and distribution of medicines, healthcare products and branded generics
Gujarat Terce Laboratories Limited is a mid‑sized Indian branded generics pharmaceutical company that manufactures and markets formulations across acute and chronic therapeutic areas from a WHO‑GMP compliant, automated facility at Chhatral; the plant has installed capacity of 270 million tablets and 108 million capsules per annum and sells through a field force spanning 13 states.
Q3 FY26 showed a modest revenue decline of 3% year‑on‑year to INR 1,229.35 lacs while EBITDA rose 8% in the quarter and 6.8% for 9M FY26, driving EBITDA margin expansion to 10.16% in Q3 and 9.03% for 9M, reflecting operational efficiency gains despite top‑line rationalisation of low‑margin businesses.
Listed peers in Pharmaceuticals: Sunrest Lifescience Ltd, Chandra Bhagat Pharma Ltd, Medicamen Organics Ltd, Medistep Healthcare Ltd, Venmax Drugs & Pharmaceuticals Ltd, Ishita Drugs & Industries Ltd.
Valuation & Returns
10 Jul 2026At ₹34 a share on 10 Jul 2026, Gujarat Terce Laboratories Ltd (GUJTERC) was valued at a price-to-earnings ratio of 16.66x against an industry P/E of 36.41x and a price-to-book of 4.09x on a book value of ₹8.31 per share as of Mar 2025. Solomo computes return on equity of 24.55% and return on capital employed of 26.42% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2020 to Sep 2021.
- P/E
- 16.66x
- Industry P/E
- 36.41x
- P/B
- 4.09x
- EPS (TTM)
- ₹2.04
- Book value / share
- ₹8.31
- ROE
- 24.55%
- ROCE
- 26.42%
- ROA
- 6.97%
- Debt / equity
- 0.15x
- Dividend yield
- 0%
- EBITDA margin
- 7.65%
- 52-week range
- ₹29 – ₹59.78
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2021In the year ended Mar 2021, Gujarat Terce Laboratories Ltd (GUJTERC) reported revenue of ₹25.18 crore, net profit of ₹-2.52 crore and earnings per share of ₹-3.4. That compares with revenue of ₹37.54 crore and net profit of ₹0.28 crore in Mar 2020. Figures are consolidated, as filed with the exchanges.
In the quarter ended Sep 2021, revenue was ₹10.13 crore and net profit ₹0.45 crore (consolidated).
| Metric | Mar 2019 | Mar 2020 | Mar 2021 |
|---|---|---|---|
| Revenue (₹ cr) | 31.03 | 37.54 | 25.18 |
| Net profit (₹ cr) | 0.43 | 0.28 | -2.52 |
| EPS (₹) | 0.58 | 0.38 | -3.4 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 8.05% | 5.98% | 7.74% | 4.65% |
| Profit growth | - | - | - | -508.33% |
| Stock price CAGR | 14% | 31% | 9% | -30% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 40.03% of Gujarat Terce Laboratories Ltd (GUJTERC) (unchanged from the previous quarter). Market capitalisation was ₹26 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: HUF 2.02%, SAGAR SAXENA 1.35%, GANESH VETRIVEL PERIASAMY 1.25%, DHEERAJ KUMAR LOHIA 1.04%, RISHABH NEGI 1.01%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 40.03% | - | - | - | 59.97% |
| Mar 2026 | 40.03% | - | - | - | 59.97% |
| Dec 2025 | 40.03% | - | - | - | 59.97% |
| Sep 2025 | 40.03% | - | - | - | 59.97% |
| Jun 2025 | 37.03% | - | - | - | 62.97% |
| Mar 2025 | 37.03% | - | - | - | 62.97% |
| Dec 2024 | 37.03% | - | - | - | 62.97% |
| Sep 2024 | 37.03% | - | - | - | 62.97% |